RT Journal Article
T1 A multi-stakeholder approach in optimising patients' needs in the benefit assessment process of new metastatic breast cancer treatments.
A1 Cardoso, Fatima
A1 Wilking, Nils
A1 Bernardini, Renato
A1 Biganzoli, Laura
A1 Espin, Jaime
A1 Miikkulainen, Kaisa
A1 Schuurman, Susanne
A1 Spence, Danielle
A1 Spitz, Sabine
A1 Ujupan, Sonia
A1 Zernik, Nicole
A1 Gordon, Jenn
K1 Health technology assessment
K1 Metastatic breast cancer
K1 Patient preferences
K1 Policy
K1 Stakeholders
K1 Treatment benefit
AB There is a growing understanding as science evolves that different cancer types require different approaches to treatment evaluation, especially in the metastatic stages. The introduction of new metastatic breast cancer (MBC) treatments may be hindered by several elements, including the availability of relevant evidence related to disease-specific outcomes, the benefit assessment process around the evaluation of the clinical benefit and the patients' need of new treatments. The Steering Committee (SC) found that not all issues relevant to MBC patients are consistently considered in the current benefit assessment process of new treatments. Among these are overall survival, time-to-event endpoints (e.g. progression-free survival), patients' priorities, burden of disease, MBC-specific quality of life, value in delaying chemotherapy, route of administration, side effects and toxicities, treatment adherence and the benefit of real-world evidence. This paper calls on decision makers to (1) Include MBC-specific patient priorities and outcomes in the overall benefit assessments of new MBC treatments; (2) Enhance multi-stakeholder collaboration in order to improve MBC patient outcomes.
PB Churchill Livingstone
YR 2020
FD 2020-04-24
LK http://hdl.handle.net/10668/15630
UL http://hdl.handle.net/10668/15630
LA en
NO Cardoso F, Wilking N, Bernardini R, Biganzoli L, Espin J, Miikkulainen K, et al. A multi-stakeholder approach in optimising patients' needs in the benefit assessment process of new metastatic breast cancer treatments. Breast. 2020 Aug;52:78-87.
DS RISalud
RD Apr 6, 2025